Close Menu

Precision Oncology Business News

Financial news, mergers and acquisitions, partnerships, and alliances.

The company's pipeline includes a KIT inhibitor that will move into clinical studies this year and an EGFR inhibitor in preclinical studies.

The company is studying gedatolisib with palbociclib and endocrine therapy in patients with ER-positive, HER2-negative metastatic breast cancer.

The technology vendor and the PBM will offer a bundled platform to help guide cancer patients to the most appropriate treatments.

The Swedish bioinformatics firm sees its greatest growth potential in precision cancer diagnostics as it prepares to go public in the next 12 months.